Evidence map›Paper›PMID 35223530›Full record

ArticleFrontiers in oncology2022

Corrigendum: High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors.

Paul Takam Kamga, Aurélie Swalduz, Adrien Costantini, Catherine Julié, Jean-François Emile, Maurice Pérol, Virginie Avrillon, Sandra Ortiz-Cuaran, Pierre De Saintigny, Etienne Giroux-Leprieur

Abstract readPublished Erratum
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Paul Takam KamgaUniversité Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Aurélie SwalduzDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Adrien CostantiniUniversité Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Catherine JuliéUniversité Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Jean-François EmileUniversité Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.
Maurice PérolDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Virginie AvrillonUniv Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Sandra Ortiz-CuaranUniv Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
Pierre De SaintignyDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Etienne Giroux-LeprieurUniversité Paris-Saclay, UVSQ, EA 4340 BECCOH, Boulogne-Billancourt, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2021.747692.].

Indexed as

biomarkerepidermal growth factor receptor (EGFR)non-small cell lung cancer (NSCLC)Sonic Hedgehog (Shh)tyrosine kinase inhibitor (TKI)

Identifiers

PMID35223530
PMCPMC8867316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.